-
Zhongguo Dang Dai Er Ke Za Zhi =... Aug 2021To study the survival rate and the incidence of complications of very preterm infants and the factors influencing the survival rate and the incidence of complications.
OBJECTIVES
To study the survival rate and the incidence of complications of very preterm infants and the factors influencing the survival rate and the incidence of complications.
METHODS
The medical data of the very preterm infants with a gestational age of <32 weeks and who were admitted to the Department of Neonatology in 11 hospitals of Jiangsu Province in China from January 2018 to December 2019 were retrospectively reviewed. Their survival rate and the incidence of serious complications were analyzed. A multivariate logistic regression analysis was used to evaluate the risk factors for death and serious complications in very preterm infants.
RESULTS
A total of 2 339 very preterm infants were enrolled, among whom 2 010 (85.93%) survived and 1 507 (64.43%) survived without serious complications. The groups with a gestational age of 22-25 weeks, 2626 weeks, 27-27 weeks, 2828 weeks, 2929 weeks, 3030 weeks, and 31-31 weeks had a survival rate of 32.5%, 60.6%, 68.0%, 82.9%, 90.1%, 92.3%, and 94.8% respectively. The survival rate tended to increase with the gestational age (<0.05) and the survival rate without serious complications in each gestational age group was 7.5%, 18.1%, 34.5%, 52.2%, 66.7%, 75.7%, and 81.8% respectively, suggesting that the survival rate without serious complications increased with the gestational age (<0.05). The multivariate logistic regression analysis showed that high gestational age, high birth weight, and prenatal use of glucocorticoids were protective factors against death in very preterm infants (<0.05), and 1-minute Apgar score ≤3 was a risk factor for death in very preterm infants (<0.05); high gestational age and high birth weight were protective factors against serious complications in very preterm infants who survived (<0.05), while 5-minute Apgar score ≤3 and maternal chorioamnionitis were risk factors for serious complications in very preterm infants who survived (<0.05).
CONCLUSIONS
The survival rate is closely associated with gestational age in very preterm infants. A low 1-minute Apgar score (≤3) may increase the risk of death in very preterm infants, while high gestational age, high birth weight, and prenatal use of glucocorticoids are associated with the reduced risk of death. A low 5-minute Apgar score (≤3) and maternal chorioamnionitis may increase the risk of serious complications in these infants, while high gestational age and high birth weight may reduce the risk of serious complications.
Topics: Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Infant, Very Low Birth Weight; Pregnancy; Retrospective Studies; Survival Rate
PubMed: 34511171
DOI: 10.7499/j.issn.1008-8830.2102037 -
The Bulletin of Tokyo Dental College Dec 2021The purpose of this study was to investigate the survival of removable partial dentures with a mandibular bilateral free end saddle (BFES) and abutment teeth in a...
The purpose of this study was to investigate the survival of removable partial dentures with a mandibular bilateral free end saddle (BFES) and abutment teeth in a clinical setting. Only mandibular dentures with a BFES were included (10 or fewer present teeth, and fewer than 4 occlusal units). The endpoints were replacement of denture and loss of abutment teeth. A total of 128 dentures and 595 abutment teeth were analyzed. Nineteen dentures had to be replaced during the observation period (mean duration: 11.4±6.9 years; range: 3 to 36 years). According to Kaplan-Meier analysis, the survival rate was 93.2% at 10 years and 68.6% at 20 years. The estimated mean survival period was 27.8 years. Single-factor analysis using the log-rank test showed that no factor investigated had a significant influence. The main reason for denture replacement was loss of abutment teeth (47.4%). The survival rate of the abutment teeth was 91.3% at 10 years and 77.3% at 20 years. The analysis revealed 4 significant risk factors: male sex (hazard ratio [HR]: 1.78); premolars (HR: 1.67); a lower number of abutment teeth (HR: 3.24); and history of endodontic treatment (HR: 2.79). The removable partial dentures with a mandibular BFES in this study lasted over 20 years, and their survival was influenced by loss of abutment teeth. Dentures are used continuously over long periods of time and should therefore be designed to allow easy adjustment when abutment teeth are lost.
Topics: Dental Abutments; Denture, Partial, Removable; Humans; Male; Mandible; Retrospective Studies; Survival Rate
PubMed: 34776474
DOI: 10.2209/tdcpublication.2020-0061 -
BMC Pediatrics Aug 2022This study is a systematic review and meta-analysis on published studies about the Global Survival Rate of Graft and Patients in the Kidney Transplantation of children. (Meta-Analysis)
Meta-Analysis
BACKGROUND
This study is a systematic review and meta-analysis on published studies about the Global Survival Rate of Graft and Patients in the Kidney Transplantation of children.
METHODS
Studies that investigated the survival rate of kidney transplants published until the 30th of December 2020 were selected using a systematic search strategy in the following databases: Medline, Embase, Scopus, ProQuest, ISI Web of Science, and Cochrane. The extracted data were entered into the Excel software and STATA 16.0. The search identified 6007 study references. From the total, we excluded 1348 duplicates, 3688 reference titles and abstracts that were deemed irrelevant, and 846 references that were not original articles (i.e., letter, commentary, review) or did not meet the inclusion criteria. As such, 89 studies involving 12,330 participants were included in this meta-analysis.
RESULTS
In this study 1, 3, 5, 7 and 10-year survival rates of graft were estimated to be 92, 83, 74.40, 67.10, and 63.50%, respectively. Also, 1, 3, 5, 7 and 10-year survival rates of patients were estimated to be 99.60, 97.30, 95.20, 74.60, and 97.90%, respectively.
CONCLUSIONS
The findings suggest differences in graft and patient survival among children with kidney transplants. Although differences in ethnic origin, incompatibility with deceased donor kidneys, and types of kidney disease are unavoidable, interventions to improve preventive and living-donor transplantation are particularly needed in minority groups. In addition, more research is needed to establish and address the contribution of medical and sociocultural barriers to preferential treatment of these groups.
Topics: Child; Humans; Kidney Diseases; Kidney Transplantation; Living Donors; Minority Groups; Survival Rate
PubMed: 36002803
DOI: 10.1186/s12887-022-03545-2 -
International Journal of Implant... May 2021Currently, insufficient bone volume always occurs in the posterior maxilla which makes implantation difficult. Short implants combined with transcrestal sinus floor... (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
Currently, insufficient bone volume always occurs in the posterior maxilla which makes implantation difficult. Short implants combined with transcrestal sinus floor elevation (TSFE) may be an option to address insufficient bone volume.
PURPOSE
The clinical performance of short implants combined with TSFE was compared with that of conventional implants combined with TSFE according to the survival rate.
METHOD
In this systematic review and meta-analysis, we followed the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Articles were identified through PubMed, Embase, the Cochrane Library, and manual searching. Eligibility criteria included clinical human studies. The quality assessment was performed according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. The odds ratio (OR) with its confidence interval (CI) was considered the essential outcome for estimating the effect of short implants combined with TSFE.
RESULTS
The registration number is INPLASY202050092. Eleven studies met the inclusion criteria, including 1 cohort study and 10 cross-sectional studies. With respect to the 1-year survival rate, no significant effect was observed between short implants (length ≤ 8 mm) and conventional implants combined with TSFE (I=0%, OR=1.04, 95% CI: 0.55-1.96). Similarly, no difference was seen between the two groups regarding the survival rate during the healing period (I=10%, OR=0.74, 95% CI: 0.28-1.97) and 3-year loading (OR=1.76, 95% CI: 0.65-4.74).
CONCLUSION
There was no evidence that the survival rate of short implants combined with TSFE was lower or higher than that of conventional implants combined with TSFE when the residual bone height was poor and the implant protrusion length of short implants was less than or similar to conventional implants. Nevertheless, the results should be interpreted cautiously due to the lack of random controlled trials in our meta-analysis.
Topics: Cohort Studies; Cross-Sectional Studies; Maxillary Sinus; Observational Studies as Topic; Sinus Floor Augmentation; Survival Rate
PubMed: 34013452
DOI: 10.1186/s40729-021-00325-y -
International Journal of Circumpolar... Dec 2021The Faroese people constitute a geographically isolated population, and research on cancer in this population is sparse. Thus, this study aimed to calculate the...
The Faroese people constitute a geographically isolated population, and research on cancer in this population is sparse. Thus, this study aimed to calculate the age-standardised incidence rate (ASIR) and 5-year survival rates in head and neck cancers (HNC) in the Faroese population from 1985 to 2017. All patients registered with HNC in the Faroese Cancer Registry (FCR) from 1985 to 2017 were included. The ASIR per 100,000 (World Standard Population) and 5-year survival rates were calculated. We also calculated the distribution of tobacco, alcohol consumption, cancer stages and various timelines. 202 patients were included in the study (62% men). The ASIR for all HNC was 10.0/100,000 persons-years and was higher among men than women. Women's survival rate was significantly higher than men's (p = 0.026). The results imply that oropharyngeal cancer (OPC) had the best survival rate and was diagnosed at a significantly earlier stage. This retrospective nation-wide study showed that ASIRs and 5-year survival rates for Faroese HNC patients in general resembled the ones reported for Danish HNC patients. Timelines for Faroese HNC patients were shorter compared with Greenlandic HNC patients, but longer compared with the Danish fast track programme limits.
Topics: Denmark; Female; Head and Neck Neoplasms; Humans; Incidence; Male; Retrospective Studies; Survival Rate
PubMed: 33719929
DOI: 10.1080/22423982.2021.1894697 -
Clinics in Perinatology Mar 2021The current 5-year survival rate for cancer in infants is greater than 75% in developed countries. However, survivors of neonatal malignancies have an increased risk of... (Review)
Review
The current 5-year survival rate for cancer in infants is greater than 75% in developed countries. However, survivors of neonatal malignancies have an increased risk of late effects from their tumor or its treatment, which may lead to long-term morbidity and/or early mortality. This article reviews surgical approaches and chemotherapeutic agents commonly used in neonatal malignancies and their associated late effects. It also reviews the increased risk for late effects associated with radiation at a young age and hematopoietic stem cell transplantation at a young age.. It highlights the importance of survivor-specific multidisciplinary care in the long-term management of neonatal cancer survivors.
Topics: Cancer Survivors; Hematopoietic Stem Cell Transplantation; Humans; Neoplasms; Survival Rate; Survivors
PubMed: 33583505
DOI: 10.1016/j.clp.2020.11.009 -
The Journal of Heart and Lung... Oct 2021
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report - 2021; Focus on recipient characteristics.
Topics: Adult; Aged; Female; Global Health; Heart Diseases; Heart-Lung Transplantation; Humans; Lung Diseases; Male; Middle Aged; Registries; Societies, Medical; Survival Rate; Thoracic Surgery; Transplant Recipients
PubMed: 34419370
DOI: 10.1016/j.healun.2021.07.015 -
Journal of Thoracic Oncology : Official... Dec 2011
Topics: Data Interpretation, Statistical; Humans; Predictive Value of Tests; Survival Analysis; Survival Rate
PubMed: 22088987
DOI: 10.1097/JTO.0b013e318233d835 -
American Family Physician Mar 2018Colorectal cancer is the fourth most common cancer in the United States and has a five-year survival rate of 65%. The American Cancer Society and other experts have... (Review)
Review
Colorectal cancer is the fourth most common cancer in the United States and has a five-year survival rate of 65%. The American Cancer Society and other experts have released guidelines on surveillance, health promotion, screening for other malignancies, and management of treatment effects. Surveillance for disease recurrence should occur every three to six months for the first two to three years, then every six months for a total of five years. Each visit should include a history and physical examination, routine care for chronic medical conditions, and screening for other primary cancers according to guidelines for the general population. Topics addressed depend on the treatment utilized but generally include gastrointestinal issues, neuropathy, pain, urinary symptoms, fatigue, psychological issues, cognitive problems, sexual symptoms, and stoma care. Carcinoembryonic antigen testing should be performed at each visit in patients who are candidates for further intervention. Chest, abdomen, and pelvic computed tomography should be performed annually for five years after treatment. Colonoscopy should be repeated one year after treatment, then three years later if no advanced adenoma is identified.
Topics: American Cancer Society; Cancer Survivors; Colorectal Neoplasms; Disease Management; Humans; Population Surveillance; Prevalence; Survival Rate; Survivors; United States
PubMed: 29671505
DOI: No ID Found -
CA: a Cancer Journal For Clinicians Jan 2013Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most...
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. A total of 1,660,290 new cancer cases and 580,350 cancer deaths are projected to occur in the United States in 2013. During the most recent 5 years for which there are data (2005-2009), delay-adjusted cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.5% per year in women. Overall, cancer death rates have declined 20% from their peak in 1991 (215.1 per 100,000 population) to 2009 (173.1 per 100,000 population). Death rates continue to decline for all 4 major cancer sites (lung, colorectum, breast, and prostate). Over the past 10 years of data (2000-2009), the largest annual declines in death rates were for chronic myeloid leukemia (8.4%), cancers of the stomach (3.1%) and colorectum (3.0%), and non-Hodgkin lymphoma (3.0%). The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of approximately 1.18 million deaths from cancer, with 152,900 of these deaths averted in 2009 alone. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket and other underserved populations.
Topics: American Cancer Society; Female; Humans; Incidence; Male; Morbidity; Neoplasms; Registries; Survival Rate; United States
PubMed: 23335087
DOI: 10.3322/caac.21166